pomalidomide has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, RS; Haley, M; Hughes, CC; Muller, GW; Naziruddin, SD; Parton, A; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L | 1 |
1 other study(ies) available for pomalidomide and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
Topics: Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation; Humans; Immunologic Factors; Interleukin-2; Ionomycin; Ionophores; Isoenzymes; K562 Cells; Killer Cells, Natural; Lymphocyte Activation; Protein Kinase C; Protein Kinase C-theta; T-Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Transcription Factors | 2005 |